Related Experiment Video

Updated: Jul 3, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K

Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody

Marc S Raab1, Yael C Cohen2,3, Fredrik Schjesvold4

  • 1Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.

Leukemia
|May 15, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.2K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.4K

Related Experiment Videos

Last Updated: Jul 3, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.2K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.4K

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Articles linked to this work by shared authors, journal, and citation graph.

Toxicity-Related Treatment Cessation in Newly Diagnosed Multiple Myeloma-Risk Factors and Survival: An Analysis From the APAC and ANZ Myeloma and Related Diseases Registry.

European journal of haematology·2026

Circulating tumor plasma cells quantification in newly diagnosed transplant ineligible real world multiple myeloma patients: Comparison of single-platform flow cytometry versus next generation flow.

Cytometry. Part B, Clinical cytometry·2026

A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states.

Nature genetics·2026

Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy.

British journal of haematology·2026

MCL-1 inhibition triggers a largely reversible cardiac stress signature in a humanised mouse model.

British journal of pharmacology·2026

Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study.

Clinical lymphoma, myeloma & leukemia·2026

Clinical evaluation of AI-assisted quantitative marrow fibrosis assessment using Continuous Indexing of Fibrosis (CIF).

Leukemia·2026

Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.

Leukemia·2026

Circulating tumor cells identify a disseminated genomic high-risk phenotype within IMS-IMWG 2025 staging in newly diagnosed multiple myeloma.

Leukemia·2026

Functional characterization of snoRNA-derived RNA (sdRNA) expression in healthy hematopoiesis and acute myeloid leukemia.

Leukemia·2026

Csnk1a1 E98 mutations rewire signaling and metabolism in del(5q) myelodysplastic neoplasms.

Leukemia·2026

Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy.

Leukemia·2026

Generational safety profiles of BTK inhibitors: adverse reaction signals and real-world evidence from the FAERS database.

Frontiers in medicine·2026

Leucine-rich alpha-2 glycoprotein as a predictor of primary non-response to anti-TNF-α therapy in biologic-naïve Egyptian IBD patients.

BMC gastroenterology·2026

Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges.

MedScience·2026

Anxiety and mood disorders are associated with greater healthcare and procedural utilization in idiopathic intracranial hypertension.

Journal of neurointerventional surgery·2026

sFgl2‑enriched MSC-EVs attenuate colitis by enhancing immunoregulatory capacity.

Colloids and surfaces. B, Biointerfaces·2026

Patterns and outcomes of emergency department visits by patients receiving immune checkpoint inhibitors: a single-center, retrospective study.

Cancer treatment and research communications·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us